FDA, Biogen Idec Say HIV-Positive People Should Not Take Skin Disorder Drug Amevive
November 14, 2005
FDA and the pharmaceutical company Biogen Idec on Thursday said HIV-positive individuals should not take the company's skin drug Amevive because it might lower their CD4+ T cell counts, Reuters reports (Reuters, 11/10). The drug is approved to treat moderate to severe psoriasis, an autoimmune skin disorder (Dow Jones/Boston Globe, 11/11). In a letter to health care providers last month, Biogen contraindicated Amevive for HIV-positive patients (Reuters, 11/10). Carmen Bozic, senior director of drug safety and risk management for Biogen, wrote that the contraindication says "Amevive should not be administered to patients with HIV. Amevive reduces CD4+ T lymphocyte counts, which might accelerate disease progression or increase complications of disease in these patients" (Biogen Idec letter, October 2005).
Antiretrovirals to Remain in Short Supply if Steps Not Taken, WHO Official Says; AHF Criticizes GSK for Retrovir Supply
Impact of Gender and Sex Work on Sexual and Injecting Risk Behaviors and Their Association With HIV Positivity Among Injecting Drug Users in an HIV Epidemic in Togliatti City, Russian Federation
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.